Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Ampol Profit Surges as Refining Margins Hit Record Highs 
SK Hynix Shares Fall as Workers Reject Wage Deal 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Tesla Raises Cybertruck Prices by $5,000 in US 
Trump Buys SpaceX Shares After Record IPO 
Add as a preferred source on Google
BUFFALO, N.Y., May 03, 2018 -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, will release first quarter 2018 earnings results on May 14, 2018. The Company will host a conference call and audio webcast on Monday, May 14, 2018 at 9:00 a.m. Eastern Time.
To participate in the call, dial (855) 227-0567 (domestic) or (612) 979-9912 (international) fifteen minutes before the conference call begins and reference the conference passcode 9093904. A replay will be available approximately one hour after the recording through Monday, May 21, 2018 and can be accessed by dialing (855) 859-2056. The live conference call and replay can also be accessed via audio webcast at the Investor Relations section of the Company’s website, located at www.athenex.com. An archive will be available at this website until June 14, 2018.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple locations in Chongqing, China.
CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.
